VRVictoria Riedl

Victoria Riedl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victoria Riedl has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN

    by Luca Scarallo, Paolo Lionetti, Jaroslaw Kierkus, Lauren Collen, Victoria Riedl, Christian Jakobsen, Gemma Pujol‐Muncunill, Kaija‐Leena Kolho, Marta Velasco Rodriguez‐Belvis, Katarina Mitrova, et al.

    Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.

  • Open Access

    Real‐world data on STRIDE‐II treatment targets in a pediatric cohort with inflammatory bowel disease

    by Marie‐Luise Frank, Thu Giang Le Thi, Ina Schacker, Lena Bragagna, Milena Geist, Simon Buehler, Victoria Riedl, Sibylle Koletzko, Tobias Schwerd, Hannes Hoelz

    Objectives: STRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence‐based targets for treat‐to‐target strategies in inflammatory bowel disease (IBD). STRIDE‐II designates clinical remission, C‐reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short‐ to intermediate‐term targets, and mucosal healing as a long‐term target. This study evaluated STRIDE‐II application and disease control in a real‐world pediatric cohort. Methods: We retrospectively analyzed newly diagnosed pediatric IBD patients (ages 3–18 years) treated according to guidelines between June 2017 and January 2023. Time‐to‐reach STRIDE‐II targets and time‐to‐first flare were assessed over 52 weeks using disease activity indices, inflammatory biomarkers (CRP, FC), and endoscopy. Results: Seventy‐four patients were included (37 Crohn's disease [CD], 37 ulcerative colitis [UC]). All CD patients received primary maintenance therapy with immunomodulators or biologics, versus 51% UC patients. Clinical remission and CRP normalization occurred within 5–10 weeks; FC normalization within 12–19 weeks. By 6 months, combined targets (clinical remission plus CRP and FC normalization) were achieved by 54% of CD patients and 43% of UC patients. Clinical relapse after remission occurred more frequently in UC than in CD (67% vs. 43%, p = 0.0334). Follow‐up endoscopy at a median of 41 weeks (CD) and 52 weeks (UC) showed endoscopic healing in 7/18 (39%) CD and 13/22 (59%) UC patients. Conclusions: Most pediatric IBD patients achieved clinical remission and CRP normalization within STRIDE‐II timeframes, whereas FC normalization occurred later, and relapses—particularly in UC—remained common. The notable proportion of patients with suboptimal disease control underscores the need for continuous monitoring in pediatric IBD.